CSPN Signs Distribution Agreement with Dara BioSciences

Community Specialty Pharmacy Network, Inc (CSPN), recently announced a distribution agreement with Dara BioSciences for Soltamox (tamoxifen citrate), a nonsteroidal antiestrogen for the treatment of patients with breast cancer.

Community Specialty Pharmacy Network, Inc (CSPN), recently announced a distribution agreement with Dara BioSciences for Soltamox (tamoxifen citrate), a nonsteroidal antiestrogen for the treatment of patients with breast cancer.

Soltamox is a liquid formulation, and was made specifically for breast cancer patients who have trouble swallowing.

“This product is an important development for patients with difficulty swallowing pills or who simply prefer an oral liquid,” said Nick Calla, RPh, CSPN vice president of industry relations. “Our pharmacies will play a key role in identifying and managing the patients most in need for a liquid form of tamoxifen.”

Nick Calla and Nick Karalis, RPh, vice president of Community Specialty Pharmacy Network, are both editorial board members at Specialty Pharmacy Times. CSPN is the largest community specialty pharmacy network in the country.

For more information on Soltamox, see the product website at soltamox.com.